Radiation therapy department is located at the European Georges Pompidou (HEGP) hospital.
The radiotherapy team includes 4 seniors’ radiotherapy oncologists MD (Pr C. Durdux, head of the unit, Pr Ph. Giraud (MD, PhD), Dr J.E. Bibault (MD, PhD), Dr S. Kreps (MD)). Four fellowships and 5 residents complete the clinical team. The team includes also six senior physicists (5 MS, 1 PhD).
The radiotherapy unit takes care of adult patients with solid tumors (gastrointestinal and urologic cancers, head and neck cancers, lung cancers, breast cancers, gynecological and skin tumors) and Hodgkin lymphomas.
Since its opening in 2000, the radiotherapy unit has been developing innovative techniques in medical imaging, dosimetry and treatment devices: intensity modulated radiotherapy, irradiation with respiratory gating, stereotactic radiotherapy with a Cyberknife® and a Novalis® STX linac. All these various innovations are designed to achieve a high precision radiotherapy to better adapt irradiation fields to the tumor in order to protect organs at risk. Medical, scientific and educational projects fit into the development and assessment of these new technologies as well as in their routine deployment.
The external radiotherapy unit consists of 3 modern Clinac with a multileaf collimator (MLC), portal imaging, including a new generation linac (Novalis® STX) with a dedicated MLC for intensity modulation deliverance or stereotactic radiotherapy and a 3D image guided radiotherapy system, and a dedicated Light Speed RT CT scanner with deep inspiration breath hold techniques or with a 4D synchronized device. A Cyberknife®, an image-guided robotic radiosurgery system, completes the technical offer. The radiotherapy unit has a surgical subunit for high dose rate brachytherapy performed in gynecological and prostate cancers, and all hardware required for prostate brachytherapy with iode125 and implementation of gold markers.
This unit includes a hospitalization unit (8 beds for >24hr-hospitalization) which allow concurrent radiochemotherapy, management of complications and supportive care. Radiochemotherapy is also possible within the mutualized cancer day hospital.
All these activities are structured around multiple weekly cancer multidisciplinary team meetings including systematically at least one radiation oncologist
Physicians and Physicists of this program are strongly involved in clinical and translational research in oncology and radiotherapy.
Since the opening of HEGP (2000), 291 papers have been published on indexed journals. Particularly, we coordinate or participate in several innovative technologies projects (National Research Program) and clinical research programs: National STIC (Expensive Diagnostic and Therapeutic Innovation Support Program) on “gated radiotherapy techniques”, INCa national programs on “patient safety during radiotherapy” and “medico-economic evaluation on advanced radiotherapy techniques” (ART-ORL, ART-PELVIS), clinical trials in advanced lung, bladder, head and neck cancers (RTEP7-IFCT 14-01, LUNG ART study, Alimta-RT phase II study, Pravastatine-RT PHRC study, Androgenic alopecia and Prostate Cancer study, A multicentric prospective randomized open-label phase IIB study to evaluate radiofrequency ablation with or without stereotactic radiotherapy for non-operable hepatocellular carcinoma (HCC) INCa study, Amifostine-RT study…).
For 2 years, thanks to the collaboration with the unit of Anita Burgun (Information Science and Personalized Medicine), the service has been implementing several research topics on radiotherapy and artificial intelligence.
The Radiotherapy Program integrates 10 interns and 3 fellows each year. Physicist team will host 2 physicist students (DQPRM) in 2020.
Medical teams are widely involved in the university teaching of various tumor pathologies in Paris University and in several national teaching degrees/master’s degrees in the field of oncology :
The Radiotherapy program propose several clinical and research perspectives:
1) Clinical perspectives:
2) Research perspectives:
|Name Surname||Title/Position||Speciality||Research Unit||Resarch Team|
|Catherine Durdux||Full Prof||Radiation Oncologist||HEGP|
|Philippe Giraud||Full Prof||Radiation Oncologist||HEGP|
|Sarah Kreps||Full time physician||Radiation Oncologist||HEGP|
|Jean-Emmanuel Bibault||Full time physician||Radiation Oncologist||UMRS 1138, Centre de Recherche des Cordeliers||Information Science and Personalized Medicine|
|Antoine Dautruche||Full time physician||Radiation Oncologist||HEGP|
|Emmanuelle Fabiano||Full time physician||Radiation Oncologist||HEGP|
|Thomas Feutren||Full time physician||Radiation Oncologist||HEGP|
|Safia Maaradji||Partial time physician||Radiation Oncologist||HEGP|
|Dupont Stéphane||Full time physicist||Medical Physicist||HEGP|
|Jaffre Françoise||Full time physicist||Medical Physicist||HEGP|
|Moreau Damien||Full time physicist||Medical Physicist||HEGP|
|Om Déborah||Full time physicist||Medical Physicist||HEGP|
|Scius Maximilien||Full time physicist||Medical Physicist||HEGP|
|Toublanc Sandra||Full time physicist||Medical Physicist||HEGP|
The selected following publications highlight the strength of clinical and translational research developed in the radiotherapy program:
|Trial Name||Sponsor Title||Principal investigators, sponsors||Radiotherapy Program investigator|
|RTEP7||Randomized phase II-III study of personalizedradiotherapy dose redistribution in patients withinoperable stage III non-small cell lung cancerand a persistent FDG uptake at 42 Gy duringconcomitant radio-chemotherapy radiotherapy dose redistribution in patients with inoperable stage III non-small cell lung cancer and a persistent FDG uptake at 42 Gy during concomitant radio-chemotherapy||P. Giraud, P. Ver, IFCT||P. Giraud|
|OSAGE||Phase I-II of chemoradiation in esophagus cancer in elderly||S. Servagi, Vernat, CHRU Besançon||JE Bibault|
|NICOL||A phase-I study of nivolumab in association with radiotherapy and cisplatin in locally advanced cervical cancers followed by adjuvant nivolumab for up to 6 months||E Romano, Curie Institute||C Durdux|
|GETUG V04||Phase II randomized trial evaluating chemoradiotherapy (cisplatin versus cisplatin plus gemcitabine) as conservative treatment in operable bladder cancer||D. Azria, GETUG||C Durdux|
|GETUG 30||Post-operative adjuvant radiotherapy in locally advanced bladder cancer : phase II randomized trial||P Sargos, GETUG||S Kreps|
|PEACE 2||A Phase III of Cabazitaxel and Pelvic Radiotherapy, in localized Prostate Cancer and High-risk Features of relapse||J L Deville, Unicancer||S Kreps, JE Bibault|
|SALTORL||Trial of Laryngeal Preservation Comparing induced CT followed by RT vs CT Concomitant to RT||G Calais, GORTEC||S Kreps|
|ImmuneBOOST||Feasibility and Tolerance of Nivolumab Neoadjuvant immunotherapy in High Risk HPV Driven Oropharynx Cancer||H Mirghani, Unicancer||S Kreps|
|NORAD1||Phase III randomized trial comparing neoadjuvant chemotherapy to chemoradiation in locally advanced rectal cancers||S Benoist, GRECCAR||E Fabiano|
|PACIFIC4||Phase III randomised double-blind placebo-controlled multicenter International study of Durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of patients with stage I-II NSCLC||E Fabre, Astra Zeneca||P Giraud|
|KEYNOTE 867||A Phase 3, Randomized, Placebo-Controlled clinical Study to evaluate the safety and efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab in participants with Medically Inoperable Stages I or IIA NSCLC (KEYNOTE-867)||M Wislez, Merck||C Durdux, A Dautruche|
|CHECKMATE L73||A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)||M Wislez, BMS||C Durdux, A Dautruche|
|PRISME||Phase II trial evaluating the efficacy of stromal mesenchymal cells in late side effects of pelvic radiotherapy in failure of conventional strategies||M Mohty, APHP||C Durdux|
Centre Universitaire des Saints-Pères Etage 4 – Pièce 446B 45 rue des Saints-Pères -75006 Paris
Carina Binet : Secrétaire Général du CARPEM
Tél. : 01 76 53 43 85 – email@example.com
Aurore Hattabi, PhD : Coordinatrice Scientifique du CARPEM
Tél : 01 76 53 43 85 – firstname.lastname@example.org